JP2010536396A - タンパク質力価を増加させる方法 - Google Patents

タンパク質力価を増加させる方法 Download PDF

Info

Publication number
JP2010536396A
JP2010536396A JP2010522371A JP2010522371A JP2010536396A JP 2010536396 A JP2010536396 A JP 2010536396A JP 2010522371 A JP2010522371 A JP 2010522371A JP 2010522371 A JP2010522371 A JP 2010522371A JP 2010536396 A JP2010536396 A JP 2010536396A
Authority
JP
Japan
Prior art keywords
protein
antibody
cells
cell
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010522371A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536396A5 (enExample
Inventor
ドロテー アムブロジウス
バーバラ エネンケル
クリシュティアン エッカーマン
Original Assignee
ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト filed Critical ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト
Publication of JP2010536396A publication Critical patent/JP2010536396A/ja
Publication of JP2010536396A5 publication Critical patent/JP2010536396A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2010522371A 2007-08-29 2008-08-28 タンパク質力価を増加させる方法 Pending JP2010536396A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07115227A EP2031064A1 (de) 2007-08-29 2007-08-29 Verfahren zur Steigerung von Proteintitern
PCT/EP2008/061310 WO2009027471A1 (de) 2007-08-29 2008-08-28 Verfahren zur steigerung von proteintitern

Publications (2)

Publication Number Publication Date
JP2010536396A true JP2010536396A (ja) 2010-12-02
JP2010536396A5 JP2010536396A5 (enExample) 2011-10-13

Family

ID=39107125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010522371A Pending JP2010536396A (ja) 2007-08-29 2008-08-28 タンパク質力価を増加させる方法

Country Status (6)

Country Link
US (1) US20100297697A1 (enExample)
EP (2) EP2031064A1 (enExample)
JP (1) JP2010536396A (enExample)
KR (1) KR20100046219A (enExample)
CA (1) CA2696809A1 (enExample)
WO (1) WO2009027471A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014526884A (ja) * 2011-07-06 2014-10-09 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
JP2016512508A (ja) * 2013-03-12 2016-04-28 バイオコン・リミテッド 融合免疫調節タンパク質及びその生産方法
JP2018528214A (ja) * 2015-09-01 2018-09-27 オンコクール・エムエル・ゲーエムベーハー コイルドコイルコネクタ
JP2020141710A (ja) * 2011-07-06 2020-09-10 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
JP2021519754A (ja) * 2018-03-30 2021-08-12 アムジエン・インコーポレーテツド Ｃ末端抗体改変体

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP1878747A1 (en) * 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
ES2687808T3 (es) * 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
TWI548418B (zh) 2007-12-05 2016-09-11 中外製藥股份有限公司 Anti-NR10 / IL-31RA antibody and its use
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
TWI544077B (zh) 2009-03-19 2016-08-01 中外製藥股份有限公司 Antibody constant region change body
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EP2455403A1 (en) * 2010-11-23 2012-05-23 Pierre Fabre Medicament Homogeneous humanized antibodies against JAM-A that inhibit proliferation
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9631216B2 (en) 2011-04-29 2017-04-25 Biocon Research Limited Method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof
CN103717729B (zh) 2011-07-08 2017-11-21 动量制药公司 细胞培养方法
EP2771031B1 (en) 2011-10-28 2018-04-18 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
EP2807188B1 (en) 2012-01-27 2019-09-11 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
CN104619853B (zh) * 2012-04-23 2021-10-12 帝斯曼知识产权资产管理有限公司 多肽表达方法
PL3489254T3 (pl) * 2012-04-30 2023-01-30 Biocon Limited Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015004633A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize islet-amyloid polypeptide (iapp)
US9850302B2 (en) 2013-07-12 2017-12-26 Prothena Biosciences Limited Antibodies that recognize IAPP
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US11191832B2 (en) 2013-11-19 2021-12-07 Prothena Biosciences Limited Monitoring immunotherapy of Lewy body disease from constipation symptoms
EP3116906A1 (en) 2014-03-12 2017-01-18 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
WO2015136472A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
TWI718121B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI769570B (zh) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Ｉｌ－６受體抗體用於製備醫藥組成物的用途
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
WO2017046776A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
US10906964B2 (en) 2016-05-02 2021-02-02 Prothena Biosciences Limited Antibodies recognizing tau
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
EP3478714A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7016470B2 (ja) 2016-07-02 2022-02-07 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
JP7017013B2 (ja) 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
CA3076313A1 (en) 2017-09-28 2019-04-04 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
KR102581734B1 (ko) 2017-10-06 2023-09-22 네오토프 뉴로사이언스 리미티드 트랜스타이레틴의 검출 방법
MA51223A (fr) 2017-11-29 2020-10-07 Prothena Biosciences Ltd Formulation lyophilisée d'un anticorps monoclonal contre la transthyrétine
TWI827585B (zh) 2018-03-15 2024-01-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
SG11202104549TA (en) 2018-11-08 2021-05-28 Prothena Biosciences Ltd Antibodies recognizing tau
UA128431C2 (uk) 2018-11-26 2024-07-10 Форті Севен, Інк. ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit
TWI859197B (zh) 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體
EP3995582B1 (en) 2019-07-01 2026-04-22 Eisai R&D Management Co., Ltd. Anti-epha4 antibody
US12558423B2 (en) 2020-05-29 2026-02-24 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation
AU2021297540A1 (en) 2020-06-24 2023-02-02 Prothena Biosciences Limited Antibodies recognizing sortilin
US20240010735A1 (en) 2020-12-24 2024-01-11 Eisai R&D Management Co., Ltd. Therapeutic pharmaceutical composition for amyotrophic lateral sclerosis
EP4269588A4 (en) 2020-12-24 2025-04-23 Eisai R&D Management Co., Ltd. ANTI-EPHA4 ANTIBODIES
CN118234864A (zh) 2021-11-11 2024-06-21 卫材R&D管理有限公司 抗EphA4抗体
WO2025059486A1 (en) 2023-09-15 2025-03-20 Prothena Biosciences Limited Anti-tdp-43 antibodies and uses thereof
EP4777522A2 (en) 2023-09-15 2026-07-22 Prothena Platform Technologies Limited Methods, compositions, and kits including cell-penetrating agents
CN122070299A (zh) 2023-09-15 2026-05-19 普罗塞纳生物科学有限公司 细胞穿透剂及其用途
WO2025059487A2 (en) 2023-09-15 2025-03-20 Othair Prothena Limited Cell penetrating agents and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02163096A (ja) * 1988-09-28 1990-06-22 Eli Lilly & Co モノクローナル抗体の不均質性を減少させる方法
JP2004536580A (ja) * 2001-04-13 2004-12-09 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｖｌａ−１に対する抗体
WO2005000892A2 (en) * 2003-06-12 2005-01-06 Eli Lilly And Company Glp-1 analog fusion plroteins
WO2006068910A1 (en) * 2004-12-22 2006-06-29 Eli Lilly And Company Glp-1 analog fusion protein formulations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02163096A (ja) * 1988-09-28 1990-06-22 Eli Lilly & Co モノクローナル抗体の不均質性を減少させる方法
JP2004536580A (ja) * 2001-04-13 2004-12-09 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｖｌａ−１に対する抗体
WO2005000892A2 (en) * 2003-06-12 2005-01-06 Eli Lilly And Company Glp-1 analog fusion plroteins
WO2006068910A1 (en) * 2004-12-22 2006-06-29 Eli Lilly And Company Glp-1 analog fusion protein formulations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6013026613; ＰＡＲＡＭＰＡＬＬＩ，　Ａ．　ｅｔ　ａｌ．: '"Ｄｅｖｅｌｏｐｅｍｅｎｔ　ｏｆ　ｓｅｒｕｍ-ｆｒｅｅ　ｍｅｄｉａ　ｉｎ　ＣＨＯ-ＤＧ４４　ｃｅｌｌｓ　ｕｓｉｎｇ　ａ　ｃｅｎｔｒａｌ　ｃｏｍｐｏｓｉｔｅ　ｓｔａｔｉｓｔｉｃａｌ　ｄｅｓｉｇｎ．"' ＣＹＴＯＴＥＣＨＮＯＬＯＧＹ Ｖｏｌ．５４，　Ｎｏ．１, 200705, Ｐ．５７-６８ *
JPN6013026616; ＫＡＮＤＡ，　Ｙ．　ｅｔ　ａｌ．: '"Ｅｓｔａｂｌｉｓｈｍｅｎｔ　ｏｆ　ａ　ＧＤＰ-ｍａｎｎｏｓｅ　４，６-ｄｅｈｙｄｒａｔａｓｅ　（ＧＭＤ）　ｋｎｏｃｋｏｕｔ　ｈｏｓｔ　ｃｅｌｌ　ｌｉｎｅ：　ａ　ｎｅｗ　ｓｔｒａｔｅｇｙ　ｆｏｒ　ｇｅ' ＪＯＵＲＮＡＬ　ＯＦ　ＢＩＯＴＥＣＨＮＯＬＯＧＹ Ｖｏｌ．１３０，　Ｎｏ．３, 20070630, Ｐ．３００-３１０ *
JPN7013002069; ＴＡＫＡＩ，　Ｔ．　ｅｔ　ａｌ．: '"Ｅｘｐｒｅｓｓｉｏｎ　ｏｆ　ｈｕｍａｎｉｚｅｄ　Ｆａｂ　ｆｒａｇｍｅｎｔｓ　ｔｈａｔ　ｒｅｃｏｇｎｉｚｅ　ｔｈｅ　ＩｇＥ-ｂｉｎｄｉｎｇ　ｄｏｍａｉｎ　ｏｆ　ｈｕｍａｎ　Ｆｃ（ｅｐｓｉｌｏｎ）ＲＩａ' ＪＯＵＲＮＡＬ　ＯＦ　ＢＩＯＣＨＥＭＩＳＴＲＹ Ｖｏｌ．１２９，　Ｎｏ．１, 200101, Ｐ．５-１２ *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019000116A (ja) * 2011-07-06 2019-01-10 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
JP2020141710A (ja) * 2011-07-06 2020-09-10 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
JP2014526884A (ja) * 2011-07-06 2014-10-09 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
JP2016512508A (ja) * 2013-03-12 2016-04-28 バイオコン・リミテッド 融合免疫調節タンパク質及びその生産方法
JP2019010111A (ja) * 2013-03-12 2019-01-24 バイオコン・リミテッド 融合免疫調節タンパク質及びその生産方法
US11090381B2 (en) 2015-09-01 2021-08-17 Oncoqr Ml Gmbh Coiled-coil connector
JP2018528214A (ja) * 2015-09-01 2018-09-27 オンコクール・エムエル・ゲーエムベーハー コイルドコイルコネクタ
JP2021519754A (ja) * 2018-03-30 2021-08-12 アムジエン・インコーポレーテツド Ｃ末端抗体改変体
JP7405764B2 (ja) 2018-03-30 2023-12-26 アムジエン・インコーポレーテツド Ｃ末端抗体改変体
US11858983B2 (en) 2018-03-30 2024-01-02 Amgen Inc. C-terminal anti-sclerostin antibody variants
JP2024037881A (ja) * 2018-03-30 2024-03-19 アムジエン・インコーポレーテツド Ｃ末端抗体改変体
JP7747715B2 (ja) 2018-03-30 2025-10-01 アムジエン・インコーポレーテツド Ｃ末端抗体改変体
US12570734B2 (en) 2018-03-30 2026-03-10 Amgen Inc. C-terminal anti-sclerostin antibody variants

Also Published As

Publication number Publication date
KR20100046219A (ko) 2010-05-06
EP2195431A1 (de) 2010-06-16
WO2009027471A1 (de) 2009-03-05
CA2696809A1 (en) 2009-03-05
EP2031064A1 (de) 2009-03-04
US20100297697A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
US20100297697A1 (en) Methods for increasing protein titers
JP5481478B2 (ja) 新規調節エレメント
US9243053B2 (en) Heterologous intron within an immunoglobulin domain
EP2938728B1 (en) Artificial introns
US20140248665A1 (en) Novel intron sequences
EP2938726B1 (en) Heterologous intron within a signal peptide
JP7826509B2 (ja) 選択マーカーとしての新規グルタミン合成酵素変異体
JP2025510718A (ja) 哺乳動物細胞における選択マーカーとしての細菌グルタミン合成酵素
US20110014624A1 (en) Methods For Identifying Cells Suitable For Large-Scale Production of Recombinant Proteins
HK1156663B (en) Novel regulatory elements

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110829

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131105